EssilorLuxottica Secures FDA Authorization for Myopia Control Lens Slowing Progression 71%

EssilorLuxottica has received FDA market authorization for its Essilor Stellest lens, the first optical lens clinically proven to slow myopia progression in children. Clinical data show the lens reduces myopia progression by an average of 71% over two years, marking a significant advancement in eye care. This approval, granted under the FDA's De Novo pathway, follows the lens's earlier Breakthrough Device designation in 2021 and allows EssilorLuxottica to bring the product to U.S. eyecare professionals within weeks, following its successful international rollout. With myopia expected to affect half the global population by 2050, including over 40% of adults and 25% of children in North America, this lens represents a critical innovation in managing a growing public health issue. EssilorLuxottica positions the lens as a transformative health solution that redefines corrective lenses as medical treatments, offering new hope for children at risk of severe eye conditions linked to high myopia. Analysts highlight the importance of this FDA approval for EssilorLuxottica's growth potential in the lucrative U.S. market, complementing existing success in Asia-Pacific regions.